AR048348A1 - Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos - Google Patents

Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos

Info

Publication number
AR048348A1
AR048348A1 ARP050101227A ARP050101227A AR048348A1 AR 048348 A1 AR048348 A1 AR 048348A1 AR P050101227 A ARP050101227 A AR P050101227A AR P050101227 A ARP050101227 A AR P050101227A AR 048348 A1 AR048348 A1 AR 048348A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently selected
halo
alkoxy
heterocycloalkyl
Prior art date
Application number
ARP050101227A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR048348A1 publication Critical patent/AR048348A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones farmacéuticas y métodos para tratar trastornos y enfermedades, por ejemplo, trastornos neurodegenerativos y/o neurologicos, por ejemplo, enfermedad de Alzheimer, en un mamífero, que comprenden compuestos de formula (1). Reivindicacion 1: Un compuesto de formula (1) en la que R1 y R2 se seleccionan cada uno independientemente entre -H, alquilo C1-8, alquenilo C2-8, alcoxi C1-8, alquenoxi C2-8, hidroxialquilo C1-8, hidroxialquenilo C2-8, halo, -CN, -NO2, (CH2)qNC(=O)R6, - (CH2)qC(=O)OR5, -(CH2)qC(=O)NR6R7, -(CH2)qNR6R7, -cicloalquilo C3-8 y cicloalquenilo C5-8, en donde R1 y R2 están cada uno sustituidos de forma opcional e independiente con uno a tres sustituyentes independientemente seleccionados entre alcoxi C1-6, alquilo C1-6, halo y -OH; R3 es un grupo de formula (2) o de formula (3), cada una como se expone a continuacion en las que B está ausente o es seleccionado entre alquileno C1-8 y alquenileno C2-4; D se selecciona entre alquilo C1-8, cicloalquilo C3- 10, heterocicloalquilo (de 3-10 miembros) y heteroarilo (de 5-7 miembros); X, Y y Z se seleccionan cada uno independientemente entre H, alquilo C1-8, alquenilo C2-8, alcoxi C1-8, alquenoxi C2-8, hidroxialquilo C1-8, hidroxialquenilo C2-8, halo, -OH, -CN, -NO2, -(CH2)q-NR7R8, -(CH2)q-NHC(=O)R9, -(CH2)q-C(=O)NR7R8, -(CH2)q-C(=O)OR9, -(CH2)q-SO2R9, -S(alquilo C1-8), cicloalquilo C3-8, -(CH2)q-(heterocicloalquilo (de 3-10 miembros)), -(CH2)q-(arilo C6-14), -(CH2)q-(heteroarilo (de 4-10 miembros)) y -(CH2)q-(ariloxi C6-14); en donde dichos X, Y y Z están cada uno sustituidos de forma opcional e independiente con uno a tres sustituyentes independientemente seleccionados entre alquilo C1-8, alquenilo C2-8, alcoxi C1-8, alquenoxi C2-8, hidroxialquilo C1-8, hidroxialquenilo C2-8, halo, -OH y -CN; y en donde dicho sustituyente alcoxi de X, Y y Z está sustituido de forma opcional e independiente con uno a tres sustituyentes independientemente seleccionados entre halo, R5, R6, R7, R8 y R9 se seleccionan cada uno independientemente entre H, alquilo C1-12, alquenilo C2-12, cicloalquilo C3-10, cicloalquenilo C5-10, bicicloalquilo C5-13, bicicloalquenilo C7-13, heterocicloalquilo (de 3-10 miembros), arilo C6-14 y heteroarilo (de 5-8 miembros); en donde NR6R7 o NR7R8 pueden formar en cada caso de forma independiente y opcional un heterocicloalquilo (de 3-8 miembros); m es 0, 1, 2 o 3; n es 0, 1, 2, o 3; q es 0, 1 o 2; o una sal farmacéuticamente aceptable del mismo.
ARP050101227A 2004-04-01 2005-03-30 Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos AR048348A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55866004P 2004-04-01 2004-04-01

Publications (1)

Publication Number Publication Date
AR048348A1 true AR048348A1 (es) 2006-04-19

Family

ID=34962303

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101227A AR048348A1 (es) 2004-04-01 2005-03-30 Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos

Country Status (28)

Country Link
US (2) US7163942B2 (es)
EP (1) EP1747195A1 (es)
JP (2) JP2007530660A (es)
KR (1) KR20060130705A (es)
CN (1) CN1938266A (es)
AP (1) AP2006003729A0 (es)
AR (1) AR048348A1 (es)
AU (1) AU2005227749A1 (es)
BR (1) BRPI0509477A (es)
CA (1) CA2562114A1 (es)
CR (1) CR8669A (es)
DO (1) DOP2005000049A (es)
EA (1) EA200601607A1 (es)
EC (1) ECSP066888A (es)
GT (1) GT200500070A (es)
IL (1) IL177955A0 (es)
MA (1) MA28493B1 (es)
MX (1) MXPA06011348A (es)
MY (1) MY136718A (es)
NL (1) NL1028664C2 (es)
NO (1) NO20064989L (es)
PE (1) PE20060147A1 (es)
SV (1) SV2006002073A (es)
TN (1) TNSN06314A1 (es)
TW (1) TW200602297A (es)
UY (1) UY28825A1 (es)
WO (1) WO2005095334A1 (es)
ZA (1) ZA200607213B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE430727T1 (de) 2001-12-20 2009-05-15 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren
BRPI0509069B8 (pt) * 2004-03-23 2021-05-25 Pfizer Prod Inc compostos de imidazol e composição farmacêutica que os compreende para o tratamento de distúrbios neurodegenerativos
RS20080139A (en) * 2005-09-22 2009-05-06 Pfizer Products Inc., Imidazole coumpounds for the treatment of neurological disorders
WO2008107335A1 (en) * 2007-03-05 2008-09-12 F. Hoffmann-La Roche Ag Aminoamides as orexin antagonists
CN102088855A (zh) * 2008-05-08 2011-06-08 百时美施贵宝公司 2-芳基甘氨酰胺衍生物
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) * 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2012162249A1 (en) * 2011-05-20 2012-11-29 Benjamin Wolozin Identification of compounds that disperse tdp-43 inclusions
WO2013026021A2 (en) * 2011-08-18 2013-02-21 Buck Institute For Research On Aging Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease
CN107722012B (zh) 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS484784U (es) * 1971-06-16 1973-01-19
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5491170A (en) * 1994-12-19 1996-02-13 Warner-Lambert Company β-carboxy sulfonamide ACAT inhibitors
EP0967201A1 (en) 1998-05-20 1999-12-29 Roche Diagnostics GmbH Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
AU2002346724B2 (en) 2001-12-14 2009-04-30 Exelixis, Inc. Human ADAM-10 inhibitors
ATE430727T1 (de) 2001-12-20 2009-05-15 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren

Also Published As

Publication number Publication date
ECSP066888A (es) 2006-11-24
BRPI0509477A (pt) 2007-09-11
JP2008189673A (ja) 2008-08-21
KR20060130705A (ko) 2006-12-19
JP2007530660A (ja) 2007-11-01
US7163942B2 (en) 2007-01-16
US20050222254A1 (en) 2005-10-06
NL1028664C2 (nl) 2006-03-22
WO2005095334A1 (en) 2005-10-13
US7345095B2 (en) 2008-03-18
AU2005227749A1 (en) 2005-10-13
IL177955A0 (en) 2006-12-31
EP1747195A1 (en) 2007-01-31
MA28493B1 (fr) 2007-03-01
AP2006003729A0 (en) 2006-10-31
PE20060147A1 (es) 2006-03-08
US20070129349A1 (en) 2007-06-07
GT200500070A (es) 2005-10-31
CR8669A (es) 2006-11-01
NO20064989L (no) 2007-01-02
MXPA06011348A (es) 2006-12-15
SV2006002073A (es) 2006-05-09
MY136718A (en) 2008-11-28
UY28825A1 (es) 2005-10-31
ZA200607213B (en) 2008-04-30
NL1028664A1 (nl) 2005-10-05
TNSN06314A1 (fr) 2007-12-03
TW200602297A (en) 2006-01-16
CN1938266A (zh) 2007-03-28
CA2562114A1 (en) 2005-10-13
DOP2005000049A (es) 2005-12-15
EA200601607A1 (ru) 2007-02-27

Similar Documents

Publication Publication Date Title
AR048348A1 (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
PE20091100A1 (es) Nuevos compuestos 010
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
HRP20110196T1 (hr) 3,5-disupstituirani fenil-piperidini kao modulatori dopamina neurotransmisije
AR038971A1 (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek
AR068888A1 (es) Derivados de 1, 3, 4 - tiadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la quinesina ksp.
AR057815A1 (es) Acidos propanoicos sustituidos por 3-(4-hidroxi-fenilo) con restricciones conformacionales que resultan de utilidad para el tratamiento de trastornos metabolicos
AR084849A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
MA30025B1 (fr) (1-aza-bicyclo[3.3.1]non-4- yl)-[5-(1h-indol-5- yl)-heteroaryl]-amines en tant que ligands cholinergiques du n-achr dans le traitement de troubles psychotiques et neurodegeneratifs
AR074966A1 (es) Compuestos amino-heterociclicos
AR068055A1 (es) Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol su procedimiento de preparacion su aplicacion como medicamentos composiciones farmaceuticas y su utilizacion principalmente como inhibidores de met
DOP2005000040A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
AR050692A1 (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por tnf o por p38
AR082699A1 (es) Sales de fenotiazindiaminio, composicion farmaceutica en base al compuesto y proceso de preparacion del compuesto
AR048789A1 (es) Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
AR059671A1 (es) Compuestos de pirimidil sulfonamida que inhiben la adhesion de los leucocitos medidada por la vla-4
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR036586A1 (es) Nuevas dihidro-pteridinonas, procedimientos para su preparacion, su utilizacion como medicamentos y las formulaciones farmaceuticas que las contienen
AR049956A1 (es) DERIVADOS DE 1,3 - OXAZOLIDIN - 2 - ONA COMO INHIBIDORES DE CETP Y ELEVADORES DEL NIVEL DE LAD-C; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS.
ES2569539T3 (es) Derivados de piperidin-4-il azetidina como inhibidores de JAK1
AR054084A1 (es) Derivados de indolcarboxamida y composiciones farmaceuticas que los contienen
PE20151651A1 (es) Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina
AR080974A1 (es) Derivados piridinicos y piperazinicos moduladores de la actividad de los canales del calcio activado por depositos intracelulares(soc), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y trastornos inmunes, entre otras.
AR060432A1 (es) Tetrahidropteridinas utiles como inhibidores de las proteinas quinasas

Legal Events

Date Code Title Description
FB Suspension of granting procedure